The newborn mouse is relatively immuno-incompetent and potentially susceptible to tolerance to allogeneic cells. As a prelude to assessing the effects of monoclonal antibody (MoAb) on newborn ...
AstraZeneca to buy in vivo cell therapy company, EsoBiotec for US$ 1billion: Cambridge, UK Tuesday, March 18, 2025, 10:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceu ...
AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback